Mimedx (MDXG) Common Equity (2010 - 2026)

Mimedx's Common Equity history runs 17 years deep, the most recent figure standing at $242.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 19.81% year-over-year to $242.9 million; the TTM figure through Mar 2026 stood at $242.9 million (up 19.81% YoY), while the FY2025 annual figure was $256.5 million, up 32.85% from the prior year.
• Common Equity came in at $242.9 million for Q1 2026 at Mimedx, down from $256.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $256.5 million in Q4 2025 to a low of -$19.5 million in Q3 2022.
• A 5-year average of $112.4 million and a median of $155.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 22036.59% in 2022 and soared 13509.62% in 2024, its largest moves.
• Mimedx's Common Equity stood at -$18.0 million in 2022, then jumped by 893.4% to $142.7 million in 2023, then soared by 35.31% to $193.1 million in 2024, then jumped by 32.85% to $256.5 million in 2025, then decreased by 5.31% to $242.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $242.9 million, $256.5 million, and $238.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison